Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

Pereira, S; Caixas, U; Branco, T; Germano, I; Lampreia, F; Papoila, A; Monteiro, E

http://hdl.handle.net/10400.10/672

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Br J Clin Pharmacol. 2008 Oct, 66(4) 551-5..pdf		443.02 KB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

AIMS: Data on efavirenz in HIV/viral hepatitis co-infected patients is non-consensual, probably due to liver function heterogeneity in the patients included. METHODS: A case control study was performed on 27 HIV-infected patients, with controlled and homogenous markers of hepatic function, either mono-infected or co-infected with HBV/HCV, to ascertain the influence of viral hepatitis on efavirenz concentrations over a 2-year follow-up period. RESULTS: No differences were found in efavirenz concentrations between groups both during and at the end of the follow-up period: control (2.43 +/- 1.91 mg l(-1)) vs. co-infected individuals (2.37 +/- 0.37 mg l(-1)). CONCLUSION: It was concluded that HBV/HCV infections in themselves do not predispose to an overexposure to efavirenz.